FAQs
1. Can lifestyle choices affect the brain-immune communication?
Yes, lifestyle factors such as diet, exercise, stress management, and sleep quality can influence the brain-immune axis. For example, a healthy diet rich in fiber supports beneficial gut microbes that produce metabolites influencing brain and immune health. Regular physical activity can reduce chronic inflammation, and stress reduction techniques may help maintain balanced neuroimmune interactions.
2. Can vaccinations affect neuroimmune interactions?
Vaccinations activate the immune system to build protection against specific pathogens. While this immune activation is generally temporary and controlled, ongoing research explores how vaccines might influence neuroimmune pathways, especially in vulnerable populations, but current evidence supports their safety and benefits.
3. Can mental health treatments benefit from neuroimmunology research?
Yes, understanding the role of inflammation and immune dysfunction in psychiatric disorders is opening new avenues for treatment. Anti-inflammatory drugs or therapies targeting immune pathways may complement traditional psychiatric treatments in the future.
Reference
1. Nutma, E., Willison, H., Martino, G., et al. (2019). Neuroimmunology–the past, present and future. Clinical and Experimental Immunology, 197(3), 278.
2. Lerner, T. N., Ye, L., & Deisseroth, K. (2016). Communication in neural circuits: tools, opportunities, and challenges. Cell, 164(6), 1136-1150.
3. Engelhardt, B. (2006). Molecular mechanisms involved in T cell migration across the blood–brain barrier. Journal of neural transmission, 113, 477-485.
4. Abbott, N. J., Patabendige, A. A., Dolman, D. E., et al. (2010). Structure and function of the blood–brain barrier. Neurobiology of disease, 37(1), 13-25.
5. Kettenmann, H., Hanisch, U. K., Noda, M., et al. (2011). Physiology of microglia. Physiological reviews. 91(2) 461-553.
6. Sofroniew, M. V., & Vinters, H. V. (2010). Astrocytes: biology and pathology. Acta neuropathologica, 119, 7-35.
7. Schäffner, E., Bosch-Queralt, M., Edgar, J. M., et al. (2023). Myelin insulation as a risk factor for axonal degeneration in autoimmune demyelinating disease. Nature neuroscience, 26(7), 1218-1228.
8. Bethea, J. R., & Fischer, R. (2021). Role of peripheral immune cells for development and recovery of chronic pain. Frontiers in immunology, 12, 641588.
9. Kawakami, N., & Wekerle, H. (2024). Life history of a brain autoreactive T cell: from thymus through intestine to blood-brain barrier and brain lesion. Neurotherapeutics, 21(6), e00442.
10. Da Mesquita, S., Fu, Z., & Kipnis, J. (2018). The meningeal lymphatic system: a new player in neurophysiology. Neuron, 100(2), 375-388.
11. Shabab, T., Khanabdali, R., Moghadamtousi, S. Z., et al. (2017). Neuroinflammation pathways: a general review. International Journal of Neuroscience, 127(7), 624-633.
12. Yong, H. Y., Rawji, K. S., Ghorbani, S., et al. (2019). The benefits of neuroinflammation for the repair of the injured central nervous system. Cellular & molecular immunology, 16(6), 540-546.
13. Kempuraj, D., Thangavel, R., Natteru, P. A., et al. (2016). Neuroinflammation induces neurodegeneration. Journal of neurology, neurosurgery and spine, 1(1), 1003.
14. Kwon, H. S., & Koh, S. H. (2020). Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Translational neurodegeneration, 9(1), 42.
15. Zhang, Q., Yang, G., Luo, Y., et al. (2024). Neuroinflammation in Alzheimer’s disease: insights from peripheral immune cells. Immunity & Ageing, 21(1), 38.
16. Xu, W., Huang, Y., & Zhou, R. (2025). NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cellular & Molecular Immunology, 22, 341–355.
17. Holbrook, J. A., Jarosz-Griffiths, H. H., Caseley, E., et al. (2021). Neurodegenerative disease and the NLRP3 inflammasome. Frontiers in pharmacology, 12, 643254.
18. Dal-Bianco, A., Oh, J., Sati, P., et al. (2024). Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance. Therapeutic Advances in Neurological Disorders, 17, 17562864241306684.
19. Eva, L., Pleș, H., Covache-Busuioc, R. A., et al. (2023). A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments. Biomedicines, 11(9), 2489.
20. Varhaug, K. N., Torkildsen, Ø., Myhr, K. M., et al. (2019). Neurofilament light chain as a biomarker in multiple sclerosis. Frontiers in neurology, 10, 338.
21. Newman, M. P., Blum, S., Wong, R. C. W., et al. (2016). Autoimmune encephalitis. Internal Medicine Journal, 46(2), 148-157.
22. Rosenthal, J. F., Hoffman, B. M., & Tyor, W. R. (2020). CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. Journal of Investigative Medicine, 68(2), 321-330.
23. Alkabie, S., & Budhram, A. (2022). Testing for antibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in the diagnosis of patients with suspected autoimmune myelopathy. Frontiers in Neurology, 13, 912050.
24. Beers, D. R., & Appel, S. H. (2019). Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. The Lancet Neurology, 18(2), 211-220.
25. Suescun, J., Chandra, S., & Schiess, M. C. (2019). The role of neuroinflammation in neurodegenerative disorders. In Translational inflammation (pp. 241-267). Academic Press.
26. Müller, N., Myint, A. M., & Schwarz, M. J. (2009). The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues in Clinical Neuroscience, 11(3), 319.
27. Hou, R., & Baldwin, D. S. (2012). A neuroimmunological perspective on anxiety disorders. Human Psychopharmacology: Clinical and Experimental, 27(1), 6-14.
28. Birnbaum, R., & Weinberger, D. R. (2020). A genetics perspective on the role of the (neuro) immune system in schizophrenia. Schizophrenia research, 217, 105-113.
29. Müller, N. (2025). Immunological Approaches in the Diagnosis and Treatment of Psychiatric Disorders: A Historical Overview. Neuroimmunomodulation, 32(1), 16-23.
30. Marano, G., Mazza, M., Lisci, F. M., et al. (2023). The microbiota–gut–brain axis: psychoneuroimmunological insights. Nutrients, 15(6), 1496.
31. José Wagner Leonel, T. J., Ciurleo, G. C. V., Formiga, A. M., et al. (2024). Long COVID: neurological manifestations-an updated narrative review. Dementia & Neuropsychologia, 18, e20230076.
32. Puricelli, C., Rolla, R., Gigliotti, L., et al. (2022). The gut-brain-immune axis in autism spectrum disorders: a state-of-art report. Frontiers in Psychiatry, 12, 755171.
33. Baldi, S., Mundula, T., Nannini, G., et al. (2021). Microbiota shaping—The effects of probiotics, prebiotics, and fecal microbiota transplant on cognitive functions: A systematic review. World Journal of Gastroenterology, 27(39), 6715.
34. Tanna, T., & Sachan, V. (2014). Mesenchymal stem cells: potential in treatment of neurodegenerative diseases. Current stem cell research & therapy, 9(6), 513-521.
35. Bielekova, B., & Pranzatelli, M. R. (2017, August). Promise, progress, and pitfalls in the search for central nervous system biomarkers in neuroimmunological diseases: a role for cerebrospinal fluid immunophenotyping. In Seminars in pediatric neurology (Vol. 24, No. 3, pp. 229-239). WB Saunders.
36. Rashmi, B. A., & Anandaram, H. (2024). Enhancement of Neuroimmune Diagnosis by Artificial Intelligence. In Translational Research in Biomedical Sciences: Recent Progress and Future Prospects, 373-379. Springer.
37. Levin, L. A., Patrick, C., Choudry, N. B., et al. (2022). Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future. Frontiers in Neurology, 13, 964197.